
Some of the researchers behind the current study Anthony George, Yilun Chen, Lao Saal and Sergii Gladchuk.
Photo Credit: Ingemar Hultquist
Scientific Frontline: Extended "At a Glance" Summary: Pathlight Blood Test for Breast Cancer Recurrence
The Core Concept: A highly sensitive blood test designed to measure circulating tumor DNA (ctDNA) in patients with early breast cancer. It successfully identifies residual disease and predicts relapse long before clinical symptoms or traditional imaging can detect it.
Key Distinction/Mechanism: Unlike standard clinical imaging that waits for tumors to become physically visible, the Pathlight method tracks microscopic fragments of tumor DNA in the bloodstream. It uses a personalized approach based on the unique genetic fingerprint of a patient's original tumor, offering a faster, more cost-effective, and highly precise liquid biopsy compared to broader genetic screenings.
Major Frameworks/Components:
- Liquid Biopsy Monitoring: Non-invasive, continuous blood sampling to track treatment response from diagnosis through post-surgery recovery.
- Circulating Tumor DNA (ctDNA) Analysis: Detecting specific, early-arising genetic alterations that represent the tumor's unique signature.
- Precision Prognostics: Outperforming standard pathological complete response (pCR) by identifying patients whose ctDNA levels do not decline during therapy, accurately signaling a high recurrence risk.





.jpg)
.png)



.png)


